Journal
CLINICAL ENDOCRINOLOGY
Volume 73, Issue 1, Pages 30-34Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2265.2009.03766.x
Keywords
-
Categories
Funding
- Chief Scientist Office in Scotland
- Chief Scientist's Office, Scotland, UK
- Amgen, Australia
- Pfizer
- GSK
- Novartis
- Amgen
- Chief Scientist Office [CZH/4/395] Funding Source: researchfish
Ask authors/readers for more resources
Objective To describe mortality and disease-specific morbidities in patients with mild primary hyperparathyroidism (PHPT). Design Retrospective population-based observational study. Setting Tayside, Scotland, from 1997 to 2006. Participants Patients with mild PHPT were selected from a pre-defined PHPT cohort between 1997 and 2006. Main outcome measures Standardised mortality ratios (SMRs) were examined for all-cause mortality, as well as cardiovascular and cancer mortality. Standardised morbidity ratios and standardised incidence ratios were also calculated for eleven observed co-morbidities. Results In total, there were 1683 (69 1% female) patients identified with mild PHPT in Tayside. Patients were found to have an increased risk of all-cause mortality and cardiovascular mortality (SMR-all cause 2 62, 95% CI 2.39-2.86; SMR-cardiovascular 2.68, 95% CI 2.34-3.05). Patients with mild PHPT had a significantly increased risk of developing cardiovascular and cerebrovascular disease, renal dysfunction and fractures compared to the age- and sex-adjusted general population. Conclusions Mortality and morbidity were increased for patients with mild untreated PHPT, which is similar to more severe PHPT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available